Ignore the 20,000 Dow — watch global reflation
Dow 20,000 is here at last. No regular reader — or indeed, any sentient and sensible human being — should base any investment decision on the Dow. Its methodological flaws are irremediable. And in any case, round numbers should not matter. One brief illustration of the Dow’s primitive methodology will suffice. Just five of its stocks — Goldman Sachs, IBM, Boeing, UnitedHealth and JPMorgan Chase — account […]